Analogously, the ATTRACTION-3 trial, a multicentre, randomized phase III trial, compared the anti-PD1 nivolumab to second-line taxanes chemotherapy in patients with refractory and metastatic ESCC [23]. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.